secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-08-13T21:25:45+00:00
Accession:  0001213900-26-089270
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial to replace CEO and CFO pending stockholder approval; annual meeting set for Sept 17
--------------------------------------------------------------------------------

- CEO Cary Claiborne and CFO Vinay Shah to be terminated effective after 2026 annual meeting if stockholder proposals approved.
- Matthew Davidson, current Chief Development Officer and board member, to become President and CEO.
- New CFO to be appointed; severance payments per amended employment agreements upon release execution.
- Board composition and size changes anticipated, including resignation of legacy board members.
- 2026 annual meeting set for Sept 17, 2026; stockholder proposal deadline Aug 23, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026089270/0001213900-26-089270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026089270/ea0301965-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-089270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer